X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761136
https://endpts.com/ahead-of-likely-approval-icer-finds-gerons-imetelstat-is-not-cost-effective-at-250000-annually/
https://www.indianpharmapost.com/drug-approval/ec-expands-reblozyls-approval-for-treatment-of-myelodysplastic-syndromes-15475
https://www.onclive.com/view/fda-approval-insights-first-line-luspatercept-for-anemia-in-lower-risk-mds
https://news.bms.com/news/details/2023/U.S.-FDA-Approves-Bristol-Myers-Squibbs-Reblozyl-luspatercept-aamt-as-First-Line-Treatment-of-Anemia-in-Adults-with-Lower-Risk-Myelodysplastic-Syndromes-MDS-Who-May-Require-Transfusions/default.aspx
https://www.globenewswire.com/news-release/2023/08/29/2733042/0/en/European-Commission-approves-Roche-s-Evrysdi-for-babies-under-two-months-old-with-spinal-muscular-atrophy-SMA.html
https://endpts.com/bristol-myers-details-phiii-win-in-first-line-test-of-reblozyl-for-reducing-transfusions-in-myelodysplastic-syndrome/
https://www.fiercepharma.com/pharma/bristol-myers-4b-plan-reblozyl-takes-shape-blood-cancer-anemia-one-caveat
https://news.bms.com/news/corporate-financial/2023/U.S.-FDA-Accepts-for-Priority-Review-Supplemental-Biologics-License-Application-and-EMA-Validates-Application-for-Reblozyl-luspatercept-aamt-as-First-Line-Treatment-of-Anemia-in-Adults-with-Lower-Risk-Myelodysplastic-Syndromes-MDS/default.aspx
https://www.businesswire.com/news/home/20230302005889/en/Bristol-Myers-Squibb-Receives-European-Commission-Approval-of-Reblozyl%C2%AE-luspatercept-for-Anemia-in-Adult-Patients-with-Non-Transfusion-Dependent-Beta-Thalassemia
https://www.fiercepharma.com/pharma/bristol-myers-squibbs-reblozyl-scores-top-line-treat-positive-results-phase-3-trial
https://www.europeanpharmaceuticalreview.com/news/175867/new-therapy-for-anaemic-myelodysplastic-cancer-patients/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761136
https://www.forbes.com/sites/greatspeculations/2022/04/28/what-to-expect-from-bristol-myers-squibb-stock-after-q1-results/?sh=1516cc674893
https://www.prnewswire.com/news-releases/european-hematology-association---above-and-beyond-luspatercept-is-efficacious-and-well-tolerated-in-patients-with-non-transfusion-dependent--thalassemia-301310111.html
https://www.prnewswire.com/news-releases/european-hematology-association-beyond-le-luspatercept-est-efficace-et-bien-tolere-chez-les-patients-atteints-de-beta-thalassemie-non-dependante-de-la-transfusion-867240609.html
https://www.prnewswire.com/news-releases/european-hematology-association---above-and-beyond-luspatercept-is-efficacious-and-well-tolerated-in-patients-with-non-transfusion-dependent--thalassemia-301310111.html
https://www.prnewswire.com/news-releases/european-hematology-association-beyond-le-luspatercept-est-efficace-et-bien-tolere-chez-les-patients-atteints-de-beta-thalassemie-non-dependante-de-la-transfusion-867240609.html
https://www.biospace.com/article/releases/health-canada-approves-reblozyl-luspatercept-new-class-of-treatment-for-adult-patients-living-with-myelodysplastic-syndromes/?s=85
https://www.businesswire.com/news/home/20201104005596/en/Acceleron-Announces-REBLOZYL%C2%AE-luspatercept-aamt-Virtual-Presentations-at-the-62nd-American-Society-of-Hematology-Annual-Meeting
https://www.biospace.com/article/health-canada-approves-reblozyl-new-class-of-treatment-for-adult-patients-living-with-beta-thalassemia/
https://www.ema.europa.eu/en/documents/assessment-report/reblozyl-epar-public-assessment-report_en.pdf
http://www.pharmatimes.com/news/ec_clears_new_class_of_anaemia_therapy_1343242
https://news.bms.com/press-release/corporatefinancial-news/us-food-and-drug-administration-fda-approves-reblozyl-luspater
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761136
https://news.bms.com/press-release/rd-news/new-england-journal-medicine-publishes-results-pivotal-phase-3-believe-trial-r
https://www.fda.gov/advisory-committees/updated-public-participation-information-december-18-2019-meeting-oncologic-drugs-advisory-committee
https://www.fiercepharma.com/marketing/can-biohaven-challenge-allergan-abbvie-goliath-migraine-ceo-coric-thinks-so
https://www.fiercepharma.com/pharma/blockbuster-balance-celgene-s-reblozyl-faces-fda-committee-for-mds
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761136
https://www.prnewswire.com/news-releases/fda-approves-first-therapy-to-treat-patients-with-rare-blood-disorder-300954846.html
Market Place
Share 
